David Krupa
Atara Biotherapeutics (United States)(US)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Psoriasis: Treatment and Pathogenesis, Growth Hormone and Insulin-like Growth Factors, Inflammatory mediators and NSAID effects, Asthma and respiratory diseases
Most-Cited Works
- → Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.(1996)260 cited
- → Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure1(1998)161 cited
- → A Randomized, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rofecoxib in the Treatment of Chronic Nonbacterial Prostatitis(2003)157 cited
- → Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585(1996)99 cited
- → Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal1(2000)98 cited
- → Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.(1993)98 cited
- → In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin(1992)93 cited
- → Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles(1994)84 cited
- → Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women1(2001)79 cited
- → Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis(1995)79 cited